Skip to main content
Evidence Snapshot

Activin receptor type-1-like

CHEMBL5311 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:21:27Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5311
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Activin receptor type-1-like as ChEMBL target CHEMBL5311, mapped to UniProt P37023. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Activin receptor type-1-like
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5311
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P37023
Activin receptor type-1-like
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Activin receptor type-1-like matters

As of 2026-09-13

Activin receptor type-1-like is reviewed as Activin receptor type-1-like (UniProt P37023); Activin receptor type-1-like shows clinical signal disease relevance led by hepatocellular carcinoma. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 788 compounds, and 186 assays, with lead potency reaching pChEMBL 9.0.

Disease context
hepatocellular carcinoma

Activin receptor type-1-like shows clinical signal disease relevance led by hepatocellular carcinoma. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include ASCRINVACUMAB.

Start review with hepatocellular carcinoma because it currently carries clinical signal support. Linked drugs include ASCRINVACUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 788 compounds, and 186 assays for this target. The dominant activity type is IC50. CHEMBL3667966 is the current potency anchor at pChEMBL 9.0.

Use CHEMBL3667966 as the tractability anchor when discussing potency (pChEMBL 9.0).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 9.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Activin receptor type-1-like matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P37023, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hepatocellular carcinoma is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

788
Total Compounds
186
Total Assays
4
Approved Drugs
IC50: 649.0, EC50: 8.0, KD: 149.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3667966
 9.0 IC50 —
No preferred name
CHEMBL3667990
 9.0 IC50 —
No preferred name
CHEMBL3818173
 9.0 IC50 —
No preferred name
CHEMBL3667999
 8.9 IC50 —
No preferred name
CHEMBL3667967
 8.9 IC50 —

Approved Drugs

Structure Compound First Approval
VANDETANIB
CHEMBL24828
 2011
DASATINIB
CHEMBL5416410
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:21:27Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5311